Eyepoint Bio
Highly Engaged Employees
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
480 Pleasant St Ste C400, Watertown, Mas...Website
eyepoint.bioRevenue
$7.6 MillionStock Symbol
EYPTIndustry
About Eyepoint Bio
Eyepoint Bio Org Chart
Is Eyepoint Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Eyepoint Bio launches new products
Website visits: Recent activity has been detected on your website
Eyepoint Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Eyepoint Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Eyepoint Bio
Check out if Eyepoint Bio is spiking on competitors!
Funding: Get notified immidiatlly once Eyepoint Bio has new funding data
Click to see if Eyepoint Bio had a recent Job posting/layoffs
Check if Eyepoint Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Eyepoint Bio
Find more new buyers
Company Profile Activity
Activity Insights
Eyepoint Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eyepoint Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eyepoint Bio.
Eyepoint Bio News & Media
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients ––EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eyepoint Bio
Eyepoint.bio is a forward-thinking biotechnology company focused on advancing precision health through innovative bioinformatics and data-driven discovery. The company integrates cutting-edge computational biology with real-world clinical insights to accelerate the development of targeted therapies and diagnostics. By leveraging large-scale biologi... Read More